GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

ITonis ITNS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ITonis

Its shares trade under the ticker ITNS. It has been listed since 21 February 2007. In the fiscal year to 30 November 2025, it reported revenue of $153 and a net loss of $11,322. At that date it held total assets of $136,401 and shareholders' equity of −$1.1m.

Itonis, Inc. engages in the distribution of its homeopathic anti-nausea product to the medical and pharmaceutical industry. The company is headquartered in Lake Forest, California. The company went IPO on 2007-02-21. The Company, through the Itonis Pharmaceuticals division, produces and markets over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company’s Emesyl nausea relief product focuses on the general public who suffers from nausea. Emesyl products are available for purchase at https://www.amazon.com and www.Emesyl.com. The firm's subsidiaries include Itonis Holdings, Inc. and Paramount Discoveries, Inc.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Feb 2007

Leadership

Pay as last reported

  • Thomas RobertsPresident, Chief Executive Officer, Chief Financial Officer, Director$5,800
  • Lawrence HaberSenior Vice President, Chief Administrative Officer, General Counsel, Secretary
  • Antonin KralChief Technical Officer, Director, since 2006
  • Iain FidlinDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Itonis Inc distributes homeopathic anti-nausea products to the medical industry.
  • The company markets Emesyl products through Amazon and its own website.
  • Itonis Pharmaceuticals division produces preparations for common ailments and chronic diseases.

Weaknesses

  • The source description is treated as untrusted facts for this analysis.
  • Specific financial data points are not provided in the input.
  • Market share details are absent from the available information.

Opportunities

  • The company can expand its distribution channels beyond current platforms.
  • Growing demand for homeopathic remedies offers potential market growth.
  • Partnerships with pharmaceutical firms could enhance product reach.

Threats

  • Regulatory scrutiny on homeopathic products may impact sales.
  • Competition from established pharmaceutical companies poses a risk.
  • Untrusted source data limits reliable strategic planning.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.